Hørsholm,
CEO Bent U. Frandsen comments:
"2023 unfolded in ways we had not anticipated, primarily due to a challenging funding environment and developments in our pipeline outside our control. However, we have commenced 2024 equipped with a clear, new strategic direction, a streamlined company, and a solid Phase III validation of our ExpreS2(TM) antigen production system. Our strategic goals and capital resources establish a clear framework for our continued progress. We approach the forthcoming opportunities and challenges with enthusiasm and are committed to delivering value and pioneering solutions to our stakeholders."
Fourth quarter (October -
- Operating income amounted to 2,284 (1,583) KSEK.
- Profit/loss after financial items amounted to -19,314 (-53,287) KSEK.
- Profit/loss for the period amounted to -17,817 (-48,533) KSEK.
-
Net income per share* amounted to -0.35
(-1.29) SEK . - End of period cash balance amounted to 57,597 (110,974) KSEK.
- End of period total assets amounted to 74,255 (137,363) KSEK
- End of period equity / asset ratio amounted to 82% (75%)**
Full-year (January -
- Operating income amounted to 8,799 (6,150) KSEK.
- Profit/loss after financial items amounted to -104,555 (-126,581) KSEK.
- Profit/loss for the period amounted to -95,989 (-118,605) KSEK.
-
Net income per share* amounted to -2.08
(-3.38) SEK . - End of period cash balance amounted to 57,597 (110,974) KSEK.
- End of period total assets amounted to 74,255 (137,363) KSEK
- End of period equity / asset ratio amounted to 82% (75%)**
Figures in parenthesis are the numbers from the same period in 2022.
*The Group's net income per share: The net income for the period divided with the average number of shares for the period. For the period October to
**Equity ratio: Shareholder's equity divided by total capital.
Webcast presentation of 2023 fourth quarter and full-year results
On
Significant events during the fourth quarter
- On 23 October, the Board of Directors of
ExpreS2ion Biotech Holding AB posted a notice that shareholders were thereby convened to the Extraordinary General Meeting to be held on9 November 2023 at10:00 CET on Mindpark, Bredgatan 11, Helsingborg,Sweden . The entrance to the meeting and registration will open at09:30 CET .
-
On
9 November 2023 , ExpreS2ion held an Extraordinary General Meeting (EGM) during which a resolution was passed related to the implementation of an incentive program.
-
On
16 November 2023 , ExpreS2ion announced financial results for the third quarter of 2023.
-
On
1 December 2023 , ExpreS2ion announced the award of a Horizon Europe grant amounting to8 million EUR , approximately90 million SEK , to the VICI-Disease consortium, of which 53% is direct contribution for ExpreS2ion's part of the project costs. The aim is to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate within four years.
Certified Adviser
This press release constitutes inside information that
For further information about ExpreS2ion
Bent U. Frandsen, CEO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2(TM), for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2(TM), includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with
https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-financial-results-for-the-fourth-quarter-and-full-year-2023,c3924553
https://mb.cision.com/Main/14402/3924553/2590010.pdf
https://mb.cision.com/Public/14402/3924553/b078664001fec88f.pdf
(c) 2024 Cision. All rights reserved., source